Moderna wins EU backing for use of BA.1 targeting Omicron booster in children
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) announced Friday that an expert panel of the European Medicines Agency (EMA) endorsed the use of its BA.1 targeting bivalent vaccine mRNA-1273.214 as a booster shot in children aged 6 â 11 years.
Accordingly, the EMAâs Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion to recommend a change to the marketing authorization granted for the company to include a booster dose of the vaccine for the age group.
The vaccine named Spikevax, adjusted for the Original COVID strain and Omicron BA.1 subvariant, will therefore be available in Europe for children (6-11 years) as a booster shot at least three months from the last COVID-19 vaccine dose. 
The decision is subject to authorization from the European Commission. The company has supported the pediatric application with clinical trial data for its original vaccine, Spikevax, and Phase 2/3 data for BA.1 targeting bivalent vaccine.

In September, CHMP backed BA.1 bivalent shot as a booster vaccine for people aged 12 years and above.